Vytal's core product, NeurOS, uses a novel meta-learning gaze-tracking algorithm to derive ocular biometrics from laptops and smartphones in minutes. The company pivoted from attempting to directly diagnose neurodegenerative disease to outputting quantifiable ocular biomarkers that doctors can interpret. NeurOS is being released first as a web app, with a smartphone app planned later; its workflow includes calibration and four eye-movement tests that produce metrics like saccadic latency. Vytal says its beta list reached 300+ people in seven days. The founders emphasize democratizing early detection and longitudinal evaluation of brain diseases and target a TAM of roughly 2 billion people at risk for neurologic disease. The team has attracted clinical and academic advisers, including Dr. Anita Gupta on the board and Dr. Sergeui Netessine as an advisor, and is pursuing clinical-trial customers as a near-term go-to-market route.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2023